Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GeneCode
Tallinn, Estonia
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical small-molecule GDNF receptor agonists have shown neuroprotective effects in animal models of Parkinson’s disease and in human dopamine neuron models, supporting a disease-modifying mechanism, but no clinical trial data are reported yet.[2]
- Therapeutic areas
- OphthalmologyNeurologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
European Innovation Council (EIC) Scaling Club networkEnterprise Estonia / Estonian Business and Innovation Agency (Applied Research Program funding)
Beyond the preview
Go deeper on GeneCode.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneCode.